LLY

900.42

-0.89%↓

UNH

598.87

+0.84%↑

NVO

129.77

-1.66%↓

JNJ

167.37

+0.45%↑

ABBV

199.41

+1.61%↑

LLY

900.42

-0.89%↓

UNH

598.87

+0.84%↑

NVO

129.77

-1.66%↓

JNJ

167.37

+0.45%↑

ABBV

199.41

+1.61%↑

LLY

900.42

-0.89%↓

UNH

598.87

+0.84%↑

NVO

129.77

-1.66%↓

JNJ

167.37

+0.45%↑

ABBV

199.41

+1.61%↑

LLY

900.42

-0.89%↓

UNH

598.87

+0.84%↑

NVO

129.77

-1.66%↓

JNJ

167.37

+0.45%↑

ABBV

199.41

+1.61%↑

LLY

900.42

-0.89%↓

UNH

598.87

+0.84%↑

NVO

129.77

-1.66%↓

JNJ

167.37

+0.45%↑

ABBV

199.41

+1.61%↑

Начало・Списък с акции・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Отворен

Сектор Здравеопазване

49.23 1.17

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

47.97

Максимум

49.31

Ключови измерители
By Trading Economics
Приходи	14B 1.7B
Продажби	300M 12B
P/E Средно за сектора	14.05 103.001
EPS	2.07
Марж на печалбата	13.77
Служители	34,100
EBITDA	13B 4.4B

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+1.4 upside

Дивиденти
By Dow Jones
Следващи печалби	31.10.2024 г.
Следваща дата на дивидент	30.10.2024 г.
Следваща дата на екс-дивидент	3.10.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	101B
Предишно отваряне	48.06
Предишно затваряне	49.23

Настроения в новините

By Acuity

30%

70%

52 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

48.485 / 49.92 Подкрепа & съпротива

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.07.2024 г., 14:08 ч. UTC

Печалби

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

26.07.2024 г., 11:54 ч. UTC

Печалби

Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales

25.04.2024 г., 14:38 ч. UTC

Печалби

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

25.04.2024 г., 11:52 ч. UTC

Печалби

Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss

16.08.2024 г., 11:30 ч. UTC

Топ новини

The Feds Are 'Playing Nice' With Pharma, at Least for Now -- Heard on the Street -- WSJ

8.08.2024 г., 10:30 ч. UTC

Топ новини

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

29.07.2024 г., 10:30 ч. UTC

Топ новини

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

26.07.2024 г., 14:51 ч. UTC

Печалби

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

26.07.2024 г., 13:53 ч. UTC

Печалби

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

26.07.2024 г., 11:28 ч. UTC

Печалби

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com

26.07.2024 г., 11:14 ч. UTC

Печалби

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD

26.07.2024 г., 11:06 ч. UTC

Печалби

Bristol-Myers Squibb 2Q Adj Gross Margin 75.6% >BMY

26.07.2024 г., 11:06 ч. UTC

Печалби

Bristol-Myers Squibb 2Q Gross Margin 73.2% >BMY

26.07.2024 г., 11:04 ч. UTC

Печалби

Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY

26.07.2024 г., 11:04 ч. UTC

Печалби

Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY

26.07.2024 г., 10:59 ч. UTC

Печалби

Bristol-Myers Squibb 2Q EPS 83c >BMY

26.07.2024 г., 10:59 ч. UTC

Печалби

Bristol-Myers Squibb 2Q Net $1.68B >BMY

26.07.2024 г., 10:59 ч. UTC

Печалби

Bristol-Myers Squibb 2Q Rev $12.2B >BMY

26.07.2024 г., 10:59 ч. UTC

Печалби

Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY

19.06.2024 г., 05:30 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28.05.2024 г., 22:51 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25.04.2024 г., 12:36 ч. UTC

Печалби

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

25.04.2024 г., 12:31 ч. UTC

Придобивния, сливания и поглъщания

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market -- IBD

25.04.2024 г., 11:31 ч. UTC

Печалби

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags -- IBD

25.04.2024 г., 11:06 ч. UTC

Печалби

Bristol-Myers Squibb Still Sees 2024 Total Revenue Up Low-Single Digits >BMY

25.04.2024 г., 11:05 ч. UTC

Печалби

Bristol-Myers Squibb Cuts 2024 View To EPS 40c-EPS 70c >BMY

25.04.2024 г., 11:05 ч. UTC

Печалби

Bristol-Myers: Prioritizing Investing in Key Growth Brands, Optimizing Operations Across Organization >BMY

25.04.2024 г., 11:04 ч. UTC

Печалби

Bristol-Myers: Focusing Resources on R&D Programs With Potential to Deliver Greatest Return on Investment >BMY

25.04.2024 г., 11:04 ч. UTC

Печалби

Bristol-Myers: Executing Strategic Productivity Initiative Aimed at $1.5B Cost Savings by End 2025 >BMY

25.04.2024 г., 11:03 ч. UTC

Печалби

Bristol-Myers Squibb 1Q Adjusted Gross Margin 75.5% >BMY

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

1.4% нагоре

12-месечна прогноза

Среден 49.18 USD 1.4%

Висок 62 USD

Нисък 33.1 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Bristol-Myers Squibb Co. през последните 3 месеца.

Техническа оценка

By Trading Central

48.485 / 49.92Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bearish events outweigh bullish events.

Настроение

By Acuity

52 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.